Latest News and Press Releases

PRESS RELEASE Emergex Generates Chikungunya Ligandome, a Milestone in the Development of its T cell Adaptive Vaccine Peptides specific to Chikungunya (CHIKV) virus expressed on surfaces of infected...

PRESS RELEASE Emergex Confirms Synthesis of a CD8+ T cell Adaptive Vaccine for Smallpox and Monkeypox Vaccine construct comprised predominantly of peptides from early “eclipse phase” antigens...

PRESS RELEASE Emergex Acquires Intradermal and Patch Drug Delivery Technology with Its Manufacturing Equipment from Zosano Pharma Abingdon, Oxon, UK, 12 October 2022 – Emergex Vaccines Holding...

PRESS RELEASE Emergex Announces GMP Production of its CD8+ T cell Universal Influenza Vaccine Emergex will manufacture the candidate universal influenza vaccine to cGMP standards for use in Phase I...

PRESS RELEASE Emergex Vaccines signs Heads of Terms for a Collaboration with Molecular Biology Institute of Paraná (IBMP) in Brazil Abingdon, Oxon, UK, 1 July 2022 – Emergex Vaccines Holding Limited...

PRESS RELEASE Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma’s Micro-Needle Patch Emergex’s COVID-19 and Dengue CD8+ T cell...

PRESS RELEASE Emergex Provides an Update on First-in-Human Studies of Its Novel Dengue Fever and Coronavirus T cell Adaptive Vaccines Both studies fully recruited, with data from the Dengue Fever...

PRESS RELEASE Emergex Advances Vaccine Candidate for Tularemia, Highlighting the Potential of T cell Priming Vaccines in National Preparedness Initiatives Emergex’s CD8+ T cell Adaptive Vaccine...

PRESS RELEASE Emergex Signs Agreement with ATCC to Advance Studies of its Yellow Fever Booster Vaccine Candidate Abingdon, Oxon, UK, 7 April 2022 – Emergex Vaccines Holding Limited (‘Emergex’, or...

PRESS RELEASE Emergex Awarded £490,525 UK Aid Grant by the Department of Health and Social Care to Advance Synthetic T cell Vaccine Candidate for Chikungunya Virus Abingdon, Oxon, UK, 22 February...